Published in Cancer Weekly, May 20th, 2003
"Pooled data from 31 primary efficacy drug company trials of fluoxetine suggested no increased risk, but the short duration of these trials may have been insufficient to detect an association," scientists writing in the Journal of Clinical Epidemiology report.
"In one prospective cohort...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.